INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 283 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $560,317 | – | 10,588 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
| Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
| Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
| WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
| SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
| Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
| EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
| Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |